title: Prognostic value of p16 promoter hypermethylation in colorectal cancer: a meta-analysis.
abstract: Whether or not p16 promoter hypermethylation has any prognostic value on the survival of patients with colorectal cancer (CRC) is uncertain. A meta-analysis was therefore conducted on the overall survival involving 16 studies with 3968 patients and disease-free survival involving six studies with 1091 cases, respectively. The promoter hypermethylation was found to be significantly associated with shorter survival compared to controls, which was not only stable according to influence analysis and cumulative meta-analysis but also conclusive according to trial sequential meta-analysis. The meta-analysis supports the hypermethylation as an independent adverse prognostic factor for CRC.
authors.affiliation: 1Department of Epidemiology and Health Statistics, Qingdao University Medical College, Qingdao, Shandong Province, China.
authors.forename: Wenjie
authors.initials: W
authors.lastname: Jiang
authors.forename: Pei-Ge
authors.initials: PG
authors.lastname: Wang
authors.forename: Yuzhu
authors.initials: Y
authors.lastname: Zhan
authors.forename: Dongfeng
authors.initials: D
authors.lastname: Zhang
mesh_terms: D015179:Colorectal Neoplasms / Q000235:genetics*; D019941:Cyclin-Dependent Kinase Inhibitor p16; D019175:DNA Methylation; D015972:Gene Expression Regulation, Neoplastic; D019942:Genes, p16; D006801:Humans; D009363:Neoplasm Proteins / Q000235:genetics*; D011379:Prognosis; D011401:Promoter Regions, Genetic; D011446:Prospective Studies; D016019:Survival Analysis
chemical_list: C000614131:CDKN2A protein, human; D019941:Cyclin-Dependent Kinase Inhibitor p16; D009363:Neoplasm Proteins